S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
Dems' climate, energy, tax bill clears initial Senate hurdle
NASDAQ:PACB

Pacific Biosciences of California - PACB Stock Forecast, Price & News

$6.06
+0.25 (+4.30%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.27
▼
$6.08
50-Day Range
$3.93
▼
$6.17
52-Week Range
$3.85
▼
$34.95
Volume
6.46 million shs
Average Volume
6.03 million shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.60

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
190.4% Upside
$17.60 Price Target
Short Interest
Healthy
16.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Pacific Biosciences of California in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.39) to ($1.23) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

462nd out of 1,283 stocks

Analytical Instruments Industry

16th out of 35 stocks

See Top Rated MarketRank™ Stocks Here
PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler reduced their target price on shares of Pacific Biosciences of California from $13.00 to $6.00 and set a "na" rating on the stock in a research note on Sunday, May 15th. Canaccord Genuity Group reduced their target price on shares of Pacific Biosciences of California from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday. Cantor Fitzgerald cut their price target on shares of Pacific Biosciences of California from $23.00 to $19.00 in a report on Thursday, May 5th. Finally, Cowen set a $9.00 price target on shares of Pacific Biosciences of California in a report on Tuesday, July 19th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Pacific Biosciences of California currently has an average rating of "Moderate Buy" and an average target price of $22.17.

Pacific Biosciences of California Trading Up 4.3 %

NASDAQ:PACB opened at $6.06 on Friday. The company's 50-day moving average price is $4.80 and its 200-day moving average price is $7.49. The company has a current ratio of 16.87, a quick ratio of 16.38 and a debt-to-equity ratio of 1.22. The stock has a market cap of $1.36 billion, a PE ratio of -6.59 and a beta of 1.43. Pacific Biosciences of California has a 12 month low of $3.85 and a 12 month high of $34.95.

Pacific Biosciences of California (NASDAQ:PACB - Get Rating) last issued its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.02. Pacific Biosciences of California had a negative net margin of 147.39% and a negative return on equity of 34.55%. During the same quarter in the previous year, the business posted ($0.21) EPS. Equities research analysts forecast that Pacific Biosciences of California will post -1.38 earnings per share for the current year.

Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

August 6, 2022 | americanbankingnews.com
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB)
August 4, 2022 | finance.yahoo.com
PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag
August 4, 2022 | seekingalpha.com
Pacific Biosciences of California, Inc's (PACB) CEO Christian Henry on Q2 2022 Results - Earnings Call Transcript
August 3, 2022 | nasdaq.com
Pacific Biosciences of California, Inc. Q2 Loss Increases, misses estimates
August 3, 2022 | finance.yahoo.com
PacBio Announces Second Quarter 2022 Financial Results
July 27, 2022 | seekingalpha.com
Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
July 27, 2022 | seekingalpha.com
Pacific Biosciences: Lacks Forward Upside Capture
July 25, 2022 | americanbankingnews.com
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $28.57 Consensus PT from Analysts
July 24, 2022 | americanbankingnews.com
Pacific Biosciences of California (NASDAQ:PACB) Sees Strong Trading Volume
July 23, 2022 | americanbankingnews.com
Pacific Biosciences of California (NASDAQ:PACB) Given a $9.00 Price Target by Cowen Analysts
July 18, 2022 | finance.yahoo.com
PacBio to Report Second Quarter 2022 Financial Results on August 3, 2022
July 9, 2022 | nasdaq.com
Interesting PACB Put And Call Options For November 18th
July 3, 2022 | nasdaq.com
First Week of August 12th Options Trading For Pacific Biosciences of California (PACB)
June 24, 2022 | nasdaq.com
Interesting PACB Put Options For August 5th
June 14, 2022 | finance.yahoo.com
Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer
June 6, 2022 | finance.yahoo.com
Pacific Biosciences of California (NASDAQ:PACB) dips 18% this week as increasing losses might not be inspiring confidence among its investors
May 16, 2022 | markets.businessinsider.com
Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know
May 13, 2022 | nasdaq.com
First Week of July 1st Options Trading For Pacific Biosciences of California (PACB)
May 8, 2022 | finance.yahoo.com
PacBio Collaborates with iLAC and Robotic Biology Institute to Develop Automated Workflows
May 6, 2022 | nasdaq.com
First Week of PACB June 24th Options Trading
May 5, 2022 | finance.yahoo.com
PacBio to Participate in the BofA Securities 2022 Healthcare Conference
May 5, 2022 | seekingalpha.com
Pacific Biosciences stock falls 8% as Cantor Fitzgerald cuts price target
May 5, 2022 | finance.yahoo.com
PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat
May 5, 2022 | seekingalpha.com
Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q1 2022 Results - Earnings Call Transcript
May 5, 2022 | seekingalpha.com
Pacific Biosciences of California Q1 2022 Earnings Preview
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
8/03/2022
Today
8/07/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
CIK
1299130
Web
www.pacb.com
Phone
(650) 521-8000
Fax
302-636-5454
Employees
728
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$17.60
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+190.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-181,220,000.00
Net Margins
-147.39%
Pretax Margin
-199.67%
Return on Equity
-34.55%
Return on Assets
-13.68%

Debt

Debt-to-Equity Ratio
1.22
Current Ratio
16.87
Quick Ratio
16.38

Sales & Book Value

Annual Sales
$130.51 million
Price / Sales
10.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.59 per share
Price / Book
1.69

Miscellaneous

Outstanding Shares
224,380,000
Free Float
221,242,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 54)
    Pres, CEO & Director
    Comp: $1.42M
  • Ms. Susan G. Kim (Age 46)
    Chief Financial Officer
    Comp: $671.49k
  • Mr. Mark Van Oene (Age 49)
    Chief Operating Officer
    Comp: $1.12M
  • Dr. Denis Zaccarin Ph.D. (Age 56)
    Sr. VP of Product Devel.
    Comp: $510.77k
  • Dr. Stephen Turner (Age 54)
    Co-Founder & CTO
  • Ms. Michele Farmer CPA (Age 42)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., Gen. Counsel & Corp. Sec.
  • Ms. Kathleen Lynch J.D.
    Head of Global Gov. Affairs & Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2022?

3 Wall Street research analysts have issued 1 year price objectives for Pacific Biosciences of California's shares. Their PACB stock forecasts range from $6.00 to $40.00. On average, they predict Pacific Biosciences of California's stock price to reach $17.60 in the next twelve months. This suggests a possible upside of 190.4% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California or view top-rated stocks among Wall Street analysts.

How has Pacific Biosciences of California's stock performed in 2022?

Pacific Biosciences of California's stock was trading at $20.46 at the start of the year. Since then, PACB shares have decreased by 70.4% and is now trading at $6.06.
View the best growth stocks for 2022 here.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our earnings forecast for Pacific Biosciences of California.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.02. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 34.55% and a negative net margin of 147.39%. During the same period last year, the company earned ($0.21) EPS.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California updated its FY 2022 earnings guidance on Wednesday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $161.95 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.39%), Nikko Asset Management Americas Inc. (6.39%), Mirae Asset Global Investments Co. Ltd. (0.44%), Green Alpha Advisors LLC (0.19%), Assenagon Asset Management S.A. (0.11%) and SG Americas Securities LLC (0.09%). Company insiders that own Pacific Biosciences of California stock include Christian O Henry, Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $6.06.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $1.36 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 728 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?

The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for Pacific Biosciences of California is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.